New British lung cancer drug from AstraZeneca is hailed as a 'game changer'

New British lung cancer drug from AstraZeneca is hailed as a 'game changer' A 'game-changing' British drug can halve the risk of dying from lung cancer, research has shown.

The ground-breaking trial found patients who received osimertinib after surgery were 51 per cent more likely to be alive five years later than those given a dummy pill.

The daily tablets target non-small-cell lung cancer (NSCLC) tumours among people who have a specific genetic mutation which means they have stopped responding to earlier treatments. The Daily Mail

See also:

• Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC (abstract) New England Journal of Medicine
• Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial AstraZeneca
• Lung cancer pill cuts risk of death by half, says ‘thrilling’ study The Guardian